Salestools LogoSalestools
Salestools AI-agenter
Lösningar
Resurser
Företag
Priser
Salestools Logo

Salestools

#1 AI-agent för säljteam och Go-to-Market-team. Sälj mer, snabbare, med mindre ansträngning.

Produkt

  • AI-säljagenter
  • Intentionsdata
  • Teknologidata
  • Besöksspårning
  • Medpilot
  • Social Försäljning

Lösningar

  • Kundservice
  • E-handel
  • SaaS
  • Företag
  • Småföretag

Resurser

  • Rapporten
  • Dokumentation
  • API-referens
  • Hjälpcenter
  • Blogg
  • Fallstudier
  • Webbinarier

Företag

  • Om oss
  • Karriärer
  • Press
  • Kontakt
  • Partners

Våra kontor

  • New York, HQ
  • Bukarest, AI-forskningslabb
  • Zug, Schweiz

© 2026 Salestools. Alla rättigheter förbehållna.

Datavillkor och SäkerhetSekretesspolicyAnvändarvillkorAcceptable Use
Alla system fungerar
Salestools LogoSalestools
Salestools AI-agenter
Lösningar
Resurser
Företag
Priser
Back to Reports
Fundraising

Marvell Technology

Marvell Technology Raises $70B in Public

5488 Marvell Lane, Santa Clara, CA 95054January 1, 20242 min read
Employees
7000+

Marvell Technology Raises $70B in Public


Marvell Technology has successfully raised $70B in a Public at a $75B valuation led by Public.


Company Overview


Marvell Technology is a Semiconductors company headquartered in 5488 Marvell Lane, Santa Clara, CA 95054, founded in 1995 with 7000+ employees.


Semiconductor company


Fundraising Details


  • Amount Raised: $70B
  • Round Type: Public
  • Valuation: $75B
  • Date: 2024-01-01
  • Investors: Public

About Marvell Technology


Semiconductor company The company is positioned in the Semiconductors sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 5488 Marvell Lane, Santa Clara, CA 95054
  • Founded: 1995
  • Team Size: 7000+
  • Industry: Semiconductors

What This Means


This funding round demonstrates strong investor confidence in Marvell Technology's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Semiconductors sector continues to attract significant investment as companies innovate to meet evolving market demands. Marvell Technology's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $75B valuation marks an important milestone for Marvell Technology, positioning the company among notable players in the Semiconductors industry.


Looking Ahead


With this new capital, Marvell Technology is well-positioned to execute on its growth strategy and continue building innovative solutions in the Semiconductors space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Marvell Technology, visit their headquarters at 5488 Marvell Lane, Santa Clara, CA 95054.

Company Info

Headquarters
5488 Marvell Lane, Santa Clara, CA 95054
Founded
1995
Team Size
7000+

Topics

Fundraising(2912)Public(771)SemiconductorsMarvell Technology

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free